Background: HER2/neu overexpression is highly associated with increased risk of cancer with poor
prognosis which is especially seen in breast cancer along with some other cancer types
such as gastric and ovarian cancers. Although HER2/neu overexpression is well characterized
in various cancer types, no effective therapy is yet found against it.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P01.05
Identification
Copyright
© 2018 Published by Elsevier Inc.
